Clinical trials: Mental Disorder
Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
- Trial name
- NCT03659929
- Testing
- Amphetamine Sulfate
- Where
- 31 sites in United States
- Volunteers
- 320 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie
Tourette Syndrome
Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment.
- Trial name
- NCT02581865
- Testing
- NBI-98854
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Neurocrine Biosciences
Pathological Gambling
Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
- Trial name
- NCT00132119
- Testing
- nalmefene HCl
- Volunteers
- 233 people
- Sponsor
- Somaxon Pharmaceuticals
Generalized Anxiety Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder…
- Trial name
- SILVER (NCT00322595)
- Testing
- Quetiapine fumarate, Paroxetine
- Where
- 86 sites in Argentina, Bulgaria and 13 more
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Insomnia
Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)
The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries…
- Trial name
- RUBY (NCT00482612)
- Testing
- Esmirtazapine
- Volunteers
- 526 people
- Sponsor
- Merck Sharp & Dohme LLC
Opioid Use Disorder
The Feasibility of VR for OUD
This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their…
- Trial name
- NCT06255119
- Testing
- 3D Therapy Thrive
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- 3D Therapy, LLC
Erectile Dysfunction
Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspension
This is a Phase 2, open-label, randomized crossover study assessing the effect of moderate alcohol intake on the absorption and onset of action of Hezkue® sildenafil oral suspension in adult subjects.
- Trial name
- NCT07290400
- Testing
- Hezkue Sildenafil Oral Suspension, Moderate Alcohol Intake
- Volunteers
- 36 people
- Sponsor
- Aspargo Labs, Inc
Idiopathic Hypersomnia, Excessive Daytime Sleepiness
A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia
The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) who completed the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010.
- Trial name
- NCT05458128
- Testing
- Pitolisant
- Where
- 32 sites in United States
- Volunteers
- 119 people
- Sponsor
- Harmony Biosciences Management, Inc.
Depressive Disorder and Anxiety Disorders
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.
- Trial name
- NCT00513565
- Testing
- single dose
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Agitation, Dementia
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation…
- Trial name
- NCT05276830
- Testing
- BXCL501
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- BioXcel Therapeutics Inc
Alzheimer's Disease
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
This is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escalating fashion.
- Trial name
- NCT00087789
- Testing
- CERE-110: Adeno-Associated Virus Delivery of NGF
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sangamo Therapeutics
Major Depressive Disorder
An Open-Label Study of Azetukalner in Major Depressive Disorder
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of…
- Trial name
- X-NOVA-OLE (NCT06922110)
- Testing
- Azetukalner
- Where
- 71 sites in United States, Finland and 1 more
- Volunteers
- 460 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Severe Postpartum Depression
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum…
- Trial name
- NCT02614547
- Testing
- SAGE-547
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Social Anxiety Disorder (SAD)
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.
- Trial name
- NCT07221578
- Testing
- VQW-765
- Where
- 30 sites in United States
- Volunteers
- 500 people
- Sponsor
- Vanda Pharmaceuticals
Alzheimer's Disease, Frontotemporal Dementia
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease…
- Trial name
- NCT01890343
- Testing
- florbetapir 18F, 18F-FDG
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild to Moderate Alzheimer Disease, Cognitive Impairment
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.
- Trial name
- NCT02293915
- Testing
- Sodium oligo-mannurarate 900mg
- Where
- 16 sites in China
- Volunteers
- 818 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Schizophrenia
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with…
- Trial name
- NCT02203838
- Testing
- RBP-7000
- Where
- 48 sites in United States
- Volunteers
- 500 people
- Sponsor
- Indivior Inc.
Post-acute COVID-19 Syndrome
SENSING-AI Cohort for Long COVID Patients
The prospective study will focus on the collection of biometric and psychometric data from a limited population for 1 month with the aim of complementing the SENSING-AI retrospective cohort.
- Trial name
- SENSING-AI (NCT05204615)
- Testing
- Collection of clinical, psychometric and biometric data
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Adhera Health, Inc.
Depressive Disorder, Major
Switching to Duloxetine in Patients With Depression
The purpose of this study is to help answer the following research question: Whether switching to duloxetine improves depressed mood when current treatment did not work well for patients with depression.
- Trial name
- ARDENT (NCT00696774)
- Testing
- Duloxetine
- Where
- 2 sites in South Korea
- Volunteers
- 242 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.